Insights That Move the GPCR Field Forward

Bryan Roth joins the Dr. GPCR community live this week to examine what standard models don't account for — what happens when GPCR selectivity is encoded at the receptor–transducer interface rather than the receptor alone. This is one of 12+ live Masterclasses planned for 2026, all included in Premium. Also this week: Terry Hébert previews his April 16 session on iPSC-derived models, and a new podcast episode with Joseph Kim on GPCR structural biology and drug discovery.

Integrated GPCR drug discovery demands more than isolated experiments. It requires alignment across chemistry, modeling, pharmacology, and translational strategy. This week, we introduce the newly structured Dr. GPCR University — ten reformatted masterclasses now fully integrated into Premium — and what that means for discovery teams.

The difference between orthosteric vs. allosteric mechanisms isn’t just academic — an orthosteric antagonist can hijack receptor physiology, while an allosteric modulator works with the system. That choice determines whether you risk over- or under-dosing, miss safety windows, or miss therapeutic breakthroughs.

Turn assay snapshots into predictions. Models separate orthosteric vs allosteric mechanisms and guide experiments for faster decisions in Terry’s Corner.